International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1

  • Scagliotti, Giorgio V.; 
  • Vynnychenko, Ihor; 
  • Park, Keunchil; 
  • Ichinose, Yukito; 
  • Kubota, Kaoru; 
  • 외 13명
Citations

WEB OF SCIENCE

156
Citations

SCOPUS

167

초록

Purpose We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma. Patients and Methods Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1: 1 to carboplatin (area under the curve, 6 mg/ml.min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. OS was the primary end point. Secondary end points included progression-free survival (PFS), objective response rate (ORR), adverse events (AEs), and association between placental growth factor (PLGF) change and OS. Results A total of 1,090 patients with nonsquamous NSCLC were randomly assigned (arms A/B, n = 541 of 549); of those, 890 had adenocarcinoma (n = 448 of 442). Median OS in arms A and B was 13.0 and 11.0 months, respectively (hazard ratio [HR], 0.90; 95% CI, 0.78 to 1.04; P = .14); median OS for the adenocarcinoma subset was 13.5 and 11.0 months, respectively (HR, 0.88; 95% CI, 0.75 to 1.03; P = .11). In descriptive analyses (arms A v B), median PFS was 5.6 months versus 5.4 months (P = <.001); ORR was 40% versus 26% (P < .001). There was no association between PLGF change and OS in arm A. The incidence of grade >= 3 AEs (arms A and B, 73% and 59%, respectively) and grade 5 AEs (14% and 9%, respectively) was higher with motesanib treatment. Conclusion Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset.

키워드

SOLID TUMORS; MULTIKINASE INHIBITOR; 1ST-LINE THERAPY; THYROID-CANCER; BEVACIZUMAB; PACLITAXEL; TRIAL; GEMCITABINE; COMBINATION; SAFETY
제목
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1
저자
Scagliotti, Giorgio V.; Vynnychenko, Ihor; Park, Keunchil; Ichinose, Yukito; Kubota, Kaoru; Blackhall, Fiona; Pirker, Robert; Galiulin, Rinat; Ciuleanu, Tudor-Eliade; Sydorenko, Oleksandr; Dediu, Mircea; Papai-Szekely, Zsolt; Martinez Banaclocha, Natividad; McCoy, Sheryl; Yao, Bin; Hei, Yong-jiang; Galimi, Francesco; Spigel, David R.
DOI
10.1200/JCO.2011.41.4987
발행일
2012-08-10
유형
Article
저널명
Journal of Clinical Oncology
권
30
호
23
페이지
2829 ~ 2836